DelfaGLP-1 Atlas

← Trials/Trial dossier/NCT02584075

UnknownPhase 4

Evaluate the Effect of Exenatide Treatment on Coronary Artery Endothelial Function

Asset

Exenatide

Subcutaneous · GLP-1 agonist

Listed sites

0

Recruiting sites

—

Enrollment

100

estimated

Study population

Obesity / overweight, Type 2 diabetes

Key I/E criteria

•BMI ≥25•HbA1c ≥8%

Primary endpoint

•Coronary endothelial function

Identifiers

Registered as

NCT IDNCT02584075
Org study IDExen100

Timeline

Milestones

Study first posted2015-10-22estimated
Last update posted2015-10-22estimated
Study start2015-11 (month precision)
Primary completion2017-11estimated (month precision)
Study completion2018-01estimated (month precision)

Assets

Investigational agents

Exenatide

Study populations

Who this study enrolls

Obesity / overweightType 2 diabetes

Eligibility

Who can enroll

Minimum age20 Years
Maximum age65 Years
SexAll
Healthy volunteersNot accepted

Inclusion criteria

•Females or males, and aged 20 to 65 years
•Newly diagnose type 2 diabetes mellitus with BMI>25kg/m2.
•HbA1C>8%.

Exclusion criteria

•Type 1 diabetes mellitus, diabetic ketoacidosis, diabetic hyperosmolar coma.
•Hepatic insufficiency (ALT or AST> 1.5*ULN).
•Renal insufficiency [Creatinine clearance rate (Ccr)]<60ml/min estimated from MDRD equation).
•Thyroid disease
•Use of any anti-diabetic, anti-hypertension or anti-dyslipidemia drugs.
•Pregnant or lactating woman.
•Severe anemia.
•Acute myocardial infarction or stoke.
•Other conditions at investigator's discretion.

Endpoints (7)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Glycemic / diabetes
3
Other (unclassified)
3
Cardiometabolic biomarkers
1

Glycemic / diabetes

3 endpoints
Secondary/protocol endpoint

the changes of fasting plasma glucose (FPG)

Time frame:the changes of fasting plasma glucose (FPG)(baseline, 12 weeks)

Fasting glucose, change

change from baseline, improvement

LOINC 1558-6

Secondary/protocol endpoint

the changes of HbA1C

Time frame:the changes of HbA1C(baseline, 12 weeks)

HbA1c, change

change from baseline, improvement

LOINC 4548-4

Secondary/protocol endpoint

the changes of fasting serum insulin (FINS)

Time frame:the changes of fasting serum insulin (FINS) (baseline, 12 weeks)

change from baseline, improvement

Cardiometabolic biomarkers

1 endpoint
Primary/protocol endpoint

Coronary endothelial function

Time frame:the change of coronary endothelial function(baseline, 12 weeks)

change from baseline, improvement

Other (unclassified)

3 endpoints
Secondary/protocol endpoint/low confidence

the changes of IL-1B

Time frame:the changes of IL-1B (baseline, 12 weeks)

change from baseline, improvement

Secondary/protocol endpoint/low confidence

the changes of IL-6

Time frame:the changes of IL-6 (baseline, 12 weeks)

change from baseline, improvement

Secondary/protocol endpoint/low confidence

the changes of TNF-α

Time frame:the changes of TNF-α(baseline, 12 weeks)

change from baseline, improvement

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 1, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.